Alpha 2.0
Login Register
» Authors » Birgir Hrafnkelsson

Birgir Hrafnkelsson

Explore the profile of Birgir Hrafnkelsson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 417
Followers 0
Related Specialties
Infectious Diseases
Pediatrics
Microbiology
Top 10 Co-Authors
Karl G Kristinsson
Asgeir Haraldsson
Helga Erlendsdottir
Samuel Sigurdsson
Elias Eythorsson
Kari Stefansson
Agnar Helgason
Martha A Hjalmarsdottir
Thorolfur Gudnason
Gunnsteinn Haraldsson
Published In
J Clin Microbiol
Scand J Infect Dis
Acta Paediatr
J Fam Nurs
Vaccine
Affiliations
Soon will be listed here.
Recent Articles
1.
Prevalence and risk factors of extended-spectrum beta-lactamase producing E. coli causing urinary tract infections in Iceland during 2012-2021
Halldorsdottir A, Hrafnkelsson B, Einarsdottir K, Kristinsson K
Eur J Clin Microbiol Infect Dis . 2024 Jun; 43(9):1689-1697. PMID: 38935227
Purpose: To investigate the association of potential risk factors for urinary tract infections (UTI) caused by E. coli producing ESBL vs. not producing ESBL in Iceland. Methods: Observational, case-control study...
2.
The impact and cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the paediatric immunisation programme in Iceland-A population-based time series analysis
Eythorsson E, Asgeirsdottir T, Erlendsdottir H, Hrafnkelsson B, Kristinsson K, Haraldsson A
PLoS One . 2021 Apr; 16(4):e0249497. PMID: 33831049
Introduction: Streptococcus pneumoniae is a cause of infections that range in severity from acute otitis media (AOM) to pneumonia and invasive pneumococcal disease (IPD). The 10-valent pneumococcal conjugate vaccine (PHiD-CV10)...
3.
Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland
Sigurdsson S, Eythorsson E, Erlendsdottir H, Hrafnkelsson B, Kristinsson K, Haraldsson A
Vaccine . 2020 Feb; 38(12):2707-2714. PMID: 32063434
Introduction: Pneumococcus is an important respiratory pathogen. The 10-valent pneumococcal vaccine (PHiD-CV) was introduced into the Icelandic vaccination programme in 2011. The aim was to estimate the impact of PHiD-CV...
4.
Drivers of growth for Atlantic cod (Gadus morhua L.) in Icelandic waters - A Bayesian approach to determine spatiotemporal variation and its causes
Frater P, Hrafnkelsson B, Elvarsson B, Stefansson G
J Fish Biol . 2019 May; 95(2):401-410. PMID: 31115911
This study assesses spatiotemporal and sex-specific growth of Atlantic cod Gadus morhua in Icelandic waters. We use a Bayesian approach which lends itself to fitting and comparing nested models such...
5.
The Effect of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine on H. influenzae in Healthy Carriers and Middle Ear Infections in Iceland
Sveinsdottir H, Bjornsdottir J, Erlendsdottir H, Hjalmarsdottir M, Hrafnkelsson B, Haraldsson A, et al.
J Clin Microbiol . 2019 May; 57(7). PMID: 31068412
Vaccinations with the 10-valent pneumococcal conjugated vaccine (PHiD-CV) started in Iceland in 2011. Protein D (PD) from , which is coded for by the gene, is used as a conjugate...
6.
Increase in tympanostomy tube placements despite pneumococcal vaccination, a population-based study
Eythorsson E, Sigurdsson S, Erlendsdottir H, Hrafnkelsson B, Kristinsson K, Haraldsson A
Acta Paediatr . 2019 Jan; 108(8):1527-1534. PMID: 30667099
Aim: The aim was to estimate the impact of the 10-valent pneumococcal vaccine (PHiD-CV) on tympanostomy tube placements (TTP) in children under five years of age in Iceland. Methods: This...
7.
Vaccination of Icelandic Children with the 10-Valent Pneumococcal Vaccine Leads to a Significant Herd Effect among Adults in Iceland
Quirk S, Haraldsson G, Hjalmarsdottir M, van Tonder A, Hrafnkelsson B, Bentley S, et al.
J Clin Microbiol . 2019 Jan; 57(4). PMID: 30651396
The introduction of pneumococcal conjugate vaccines (PCVs) into childhood vaccination programs has reduced carriage of vaccine serotypes and pneumococcal disease. The 10-valent PCV was introduced in Iceland in 2011. The...
8.
Impact of the 10-valent pneumococcal conjugate vaccine on antimicrobial prescriptions in young children: a whole population study
Eythorsson E, Sigurdsson S, Hrafnkelsson B, Erlendsdottir H, Haraldsson A, Kristinsson K
BMC Infect Dis . 2018 Oct; 18(1):505. PMID: 30286726
Background: Antimicrobial resistance is a public-health threat and antimicrobial consumption is the main contributor. The ten-valent pneumococcal conjugate vaccine (PHiD-CV10) was introduced into the Icelandic vaccination program in 2011. The...
9.
Effect of Vaccination on Pneumococci Isolated from the Nasopharynx of Healthy Children and the Middle Ear of Children with Otitis Media in Iceland
Quirk S, Haraldsson G, Erlendsdottir H, Hjalmarsdottir M, van Tonder A, Hrafnkelsson B, et al.
J Clin Microbiol . 2018 Sep; 56(12). PMID: 30257906
Vaccination with pneumococcal conjugate vaccines (PCVs) disrupts the pneumococcal population. Our aim was to determine the impact of the 10-valent PCV on the serotypes, genetic lineages, and antimicrobial susceptibility of...
10.
Reduction in All-Cause Acute Otitis Media in Children <3 Years of Age in Primary Care Following Vaccination With 10-Valent Pneumococcal Haemophilus influenzae Protein-D Conjugate Vaccine: A Whole-Population Study
Sigurdsson S, Eythorsson E, Hrafnkelsson B, Erlendsdottir H, Kristinsson K, Haraldsson A
Clin Infect Dis . 2018 Apr; 67(8):1213-1219. PMID: 29617959
Background: The 10-valent pneumococcal conjugate vaccine (PHiD-CV10) was introduced in Iceland in 2011, without catch-up. The aim of this study was to estimate vaccine impact (VI) on acute otitis media...